Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Killestein, J.
Right arrow Articles by Polman, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Killestein, J.
Right arrow Articles by Polman, C. H.
Related Collections
Right arrow MRI
Right arrow Multiple sclerosis
Neurology 2001;57:1129-1131
© 2001 American Academy of Neurology
Brief Communications

TNF{alpha} production by CD4+ T cells predicts long-term increase in lesion load on MRI in MS

J. Killestein, MD, N. F. Kalkers, MD, J. F. Meilof, MD PhD;, F. Barkhof, MD PhD;, R. A. W. van Lier, MD PhD; and C. H. Polman, MD PhD

From the Department of Neurology (Drs. Killestein, Kalkers, Meilof, and Polman) and the MS-MRI Center (Dr. Barkhof), Vrije Universiteit Medical Center, and the Department of Immunobiology, (Drs. Killestein and van Lier), Centraal Laboratorium Bloedtransfusiedienst, Amsterdam, the Netherlands.

Address correspondence and reprint requests to Dr. C.H. Polman, Department of Neurology, VU Medical Center, P.O. Box 7057, 1007 MB, Amsterdam, the Netherlands; e-mail: CH.Polman{at}azvu.nl

Reliable laboratory prognostic factors for MS are still lacking. The predictive value of markers of T-cell activation for long-term disease progression was investigated. Flow cytometry measurements were correlated to changes in Expanded Disability Status Scale and MR T2 lesion load over 36 months in 14 patients with secondary progressive MS. A correlation was found between the percentage of tumor necrosis factor-{alpha}-producing CD4+ T cells at baseline and the change in T2 lesion load during 3-year follow-up (r = 0.79, adjusted r2 = 0.59, p = 0.001).




This article has been cited by other articles:


Home page
 Arch NeurolHome page
E. M. Frohman, M. Filippi, O. Stuve, S. G. Waxman, J. Corboy, J. T. Phillips, C. Lucchinetti, J. Wilken, N. Karandikar, B. Hemmer, et al.
Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions
Arch Neurol, September 1, 2005; 62(9): 1345 - 1356.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. Rejdak, M. J. Eikelenboom, A. Petzold, E. J. Thompson, Z. Stelmasiak, R. H.C. Lazeron, F. Barkhof, C. H. Polman, B. M.J. Uitdehaag, and G. Giovannoni
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis
Neurology, October 26, 2004; 63(8): 1439 - 1445.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
R. Foroozan, L. M. Buono, R. C. Sergott, and P. J. Savino
Retrobulbar Optic Neuritis Associated With Infliximab
Arch Ophthalmol, July 1, 2002; 120(7): 985 - 987.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.